https://beststocks.com/ocugen-develops-groundbreaking-mucosal-vaccin/
~"National Institute of Allergy and Infectious Diseases will conduct trial of Ocugen‘s mucosal vaccine OCU500... a nasal spray. These clinical trials to commence early 2024....
The decision to license this vaccine was based on compelling evidence from a phase 3 trial, which evaluated the effectiveness of two doses in previously unvaccinated individuals. Additionally, an 875-subject booster study further reinforced the vaccine’s efficacy"~



